Living with TD? Let’s dive into the top five leading therapies for tardive dyskinesia you’ve probably never even heard ...

Tardive dyskinesia (TD) is an involuntary movement condition, meaning you can't control your movements. "Tardive" means late, and "dyskinesia" means uncontrolled movements. It's often a side ...

The asthma medication theophylline is a suitable drug for treating the rare neurological disorder ADCY5-related dyskinesia, ...

Is your medication doing more harm than good? Could it be a sign that you have tardive dyskinesia? Here's what you need to ...

KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using ...

Research from Martin Luther University suggests the asthma drug theophylline helps reduce symptoms in ADCY5-related ...

New study published in the Journal of Clinical Psychiatry reveals AI enables efficient, accurate and scalable detection of TD, representing a significant advancement in meeting the standard of care ...

Study reveals over half of long-term care residents with tardive dyskinesia do not receive standard treatment, highlighting care gaps. Less than half of patients diagnosed with tardive dyskinesia ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD ...

Videos available at [ Key points A 94-year-old man with parkinsonism, followed in our geriatric medicine clinic, presented for routine follow-up, during which his wife reported that he had a ...

According to new research, oral vertical dyskinesia (OVD), also known by the older term “rabbit syndrome,” may be part of a spectrum of symptoms of drug-induced parkinsonism and tardive ...

“I am very pleased that the clinical effect of CPL’36 has now been confirmed also for the treatment of LID dyskinesia in Parkinson’s disease,” said Celon’s CEO Maciej Wieczorek, PhD.